
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD® OMICS-One Protein Panels
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Immune Profiler Protein Panel
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD® OMICS-One Protein Panels
- Japan (Japanese)
-
Change country/language
Old Browser
Looks like you're visiting us from United States.
Would you like to stay on the current country site or be switched to your country?
BD Horizon™ BV421 Rat Anti-Human HLA-B
クローン YTH 76.3.rMAb (also known as YTH/76.3; YT76) (RUO)

Multiparameter flow cytometric analysis of HLA-B expression on Human peripheral blood leukocyte populations. Fresh whole blood was treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) to lyse erythrocytes. After washing, the leukocytes were preincubated with BD Pharmingen™ Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with either BD Horizon™ BV421 Rat IgG1, κ Isotype Control (Cat. No. 562868; Left Plot) or BD Horizon™ BV421 Rat Anti-Human HLA-B antibody (Cat. No. 569644/569645; Right Plot). The bivariate pseudocolor density plot showing the correlated expression of HLA-B (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.


Multiparameter flow cytometric analysis of HLA-B expression on Human peripheral blood leukocyte populations. Fresh whole blood was treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) to lyse erythrocytes. After washing, the leukocytes were preincubated with BD Pharmingen™ Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with either BD Horizon™ BV421 Rat IgG1, κ Isotype Control (Cat. No. 562868; Left Plot) or BD Horizon™ BV421 Rat Anti-Human HLA-B antibody (Cat. No. 569644/569645; Right Plot). The bivariate pseudocolor density plot showing the correlated expression of HLA-B (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.

Multiparameter flow cytometric analysis of HLA-B expression on Human peripheral blood leukocyte populations. Fresh whole blood was treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) to lyse erythrocytes. After washing, the leukocytes were preincubated with BD Pharmingen™ Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with either BD Horizon™ BV421 Rat IgG1, κ Isotype Control (Cat. No. 562868; Left Plot) or BD Horizon™ BV421 Rat Anti-Human HLA-B antibody (Cat. No. 569644/569645; Right Plot). The bivariate pseudocolor density plot showing the correlated expression of HLA-B (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.


BD Horizon™ BV421 Rat Anti-Human HLA-B

Regulatory Statusの凡例
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation and Storage
推奨アッセイ手順
BD® CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant™ Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant™ Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant™ Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant™ Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant™ Stain Buffer Plus (Cat. No. 566385).
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
関連製品






最近閲覧済み
The YTH 76.3rMAb is a recombinant monoclonal antibody that specifically recognizes a monomorphic epitope on the extracellular region of the Human Leukocyte Antigen-B (HLA-B) heavy chain. This major histocompatibility complex (MHC) class I antigen is comprised of a polymorphic HLA-B heavy chain, a ~45 kDa type I transmembrane glycoprotein encoded by HLA-B, that is noncovalently associated with the invariant ~12 kDa Beta-2 (β2)-microglobulin light chain encoded by B2M. Hundreds of HLA-B alleles have been reported. HLA-B is expressed on most nucleated cells and leucocytes including specialized antigen presenting cells such as thymic epithelial cells and dendritic cells. HLA-B plays a major role in the MHC-restricted presentation of small peptides, including those derived from self or foreign antigens, that can be bound by TCR expressed on CD8+ thymocytes or T cells leading to either immune tolerance, the maturation of naïve CD8+ T cells, or the activation and differentiation of CD8+ cytotoxic effector T cells or memory CD8+ T cells. HLA-B also functions as a ligand for regulatory CD8 coreceptor molecules and some CD158 molecules that serve as regulatory MHC class I antigen receptors expressed by CD8+ T cells and NK cells. The YTH 76.3rMAb is derived from the hybridoma clone YTH 76.3, with Rat IgG2a, κ isotype. YTH 76.3rMAb has variable region sequences from the original YTH 76.3 clone appended to Rat IgG1 and kappa constant region sequences.

Development References (5)
-
Burrone OR, Kefford RF, Gilmore D, Milstein C. Stimulation of HLA-A,B,C by IFN-alpha. The derivation of Molt 4 variants and the differential expression of HLA-A,B,C subsets.. EMBO J. 1985; 4(11):2855-60. (Clone-specific: Flow cytometry). View Reference
-
Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.. J Immunol. 1985; 134(5):3056-61. (Immunogen: Flow cytometry). View Reference
-
Margulies DH, Natarajan K, Rossjohn J, McCluskey J. Major Histocompatibility Complex and Its Proteins. In: Paul WE. Paul WE, ed. Fundamental Immunology 7th Edition. Philadelphia: Lippincott Williams & Wilkins; 2013:487-523.
-
Rojas RE, Balaji KN, Subramanian A, Boom WH. Regulation of human CD4(+) alphabeta T-cell-receptor-positive (TCR(+)) and gammadelta TCR(+) T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta.. Infect Immun. 1999; 67(12):6461-72. (Clone-specific: Flow cytometry). View Reference
-
Schmidt H, Gekeler V, Haas H, et al. Differential regulation of HLA class I genes by interferon.. Immunogenetics. 1990; 31(4):245-52. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.